These in vivo data confirm the previous in vitro observations that RGS10 deficiency promotes invasion and metastasis by activating the LCN2 pathway to induce EMT in breast cancer cells, and demonstrate that RGS10 has utility as a prognostic biomarker in breast cancer. The gene discussed is LCN2; the disease is breast carcinoma.